These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A structural hypothesis for BH4 responsiveness in patients with mild forms of hyperphenylalaninaemia and phenylketonuria. Erlandsen H; Stevens RC J Inherit Metab Dis; 2001 Apr; 24(2):213-30. PubMed ID: 11405341 [TBL] [Abstract][Full Text] [Related]
3. Current Advances and Material Innovations in the Search for Novel Treatments of Phenylketonuria. Delbreil P; Dhondt S; Kenaan El Rahbani RM; Banquy X; Mitchell JJ; Brambilla D Adv Healthc Mater; 2024 Oct; 13(26):e2401353. PubMed ID: 38801163 [TBL] [Abstract][Full Text] [Related]
4. Unresponsiveness to tetrahydrobiopterin of phenylalanine hydroxylase deficiency. Ponzone A; Porta F; Mussa A; Alluto A; Ferraris S; Spada M Metabolism; 2010 May; 59(5):645-52. PubMed ID: 19913839 [TBL] [Abstract][Full Text] [Related]
5. Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up. Burton BK; Longo N; Vockley J; Grange DK; Harding CO; Decker C; Li M; Lau K; Rosen O; Larimore K; Thomas J; Mol Genet Metab; 2020 Aug; 130(4):239-246. PubMed ID: 32593547 [TBL] [Abstract][Full Text] [Related]
6. Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria. Zori R; Ahring K; Burton B; Pastores GM; Rutsch F; Jha A; Jurecki E; Rowell R; Harding C Mol Genet Metab; 2019; 128(1-2):92-101. PubMed ID: 31439512 [TBL] [Abstract][Full Text] [Related]
7. Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Matalon R; Michals-Matalon K; Koch R; Grady J; Tyring S; Stevens RC Mol Genet Metab; 2005 Dec; 86 Suppl 1():S17-21. PubMed ID: 16143554 [TBL] [Abstract][Full Text] [Related]
8. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias. Blau N Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856 [TBL] [Abstract][Full Text] [Related]
9. 5-year retrospective analysis of patients with phenylketonuria (PKU) and hyperphenylalaninemia treated at two specialized clinics. Levy H; Lamppu D; Anastosoaie V; Baker JL; DiBona K; Hawthorne S; Lindenberger J; Kinch D; Seymour A; McIlduff M; Watling S; Vockley J Mol Genet Metab; 2020 Mar; 129(3):177-185. PubMed ID: 31883647 [TBL] [Abstract][Full Text] [Related]
10. New findings about neuropathological outcomes in the PKU mouse throughout lifespan. Bregalda A; Carducci C; Pascucci T; Ambrogini P; Sartini S; Pierigè F; di Carlo E; Fiori E; Ielpo D; Pagliarini M; Leuzzi V; Magnani M; Rossi L Mol Genet Metab; 2024; 143(1-2):108543. PubMed ID: 39047302 [TBL] [Abstract][Full Text] [Related]
11. Phenylalanine hydroxylase deficiency in the Slovak population: genotype-phenotype correlations and genotype-based predictions of BH4-responsiveness. Polak E; Ficek A; Radvanszky J; Soltysova A; Urge O; Cmelova E; Kantarska D; Kadasi L Gene; 2013 Sep; 526(2):347-55. PubMed ID: 23764561 [TBL] [Abstract][Full Text] [Related]
12. The effect of blood phenylalanine concentration on Kuvan™ response in phenylketonuria. Elsas LJ; Greto J; Wierenga A Mol Genet Metab; 2011 Apr; 102(4):407-12. PubMed ID: 21216643 [TBL] [Abstract][Full Text] [Related]
13. Dietary glycomacropeptide supports growth and reduces the concentrations of phenylalanine in plasma and brain in a murine model of phenylketonuria. Ney DM; Hull AK; van Calcar SC; Liu X; Etzel MR J Nutr; 2008 Feb; 138(2):316-22. PubMed ID: 18203898 [TBL] [Abstract][Full Text] [Related]
14. Phenylalanine hydroxylase genotype-phenotype associations in the United States: A single center study. Rajabi F; Rohr F; Wessel A; Martell L; Dobrowolski SF; Guldberg P; Güttler F; Levy HL Mol Genet Metab; 2019 Dec; 128(4):415-421. PubMed ID: 31623983 [TBL] [Abstract][Full Text] [Related]
15. Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria. Burnett JR IDrugs; 2007 Nov; 10(11):805-13. PubMed ID: 17968763 [TBL] [Abstract][Full Text] [Related]
16. Neurotransmitters Disorders with Mild Hyperphenylalaninemia: The Ones That Should Not Be Missed. Thoalnoon OA; Kareem AA; Hammoodi HZ Arch Razi Inst; 2023 Apr; 78(2):667-673. PubMed ID: 37396747 [TBL] [Abstract][Full Text] [Related]
17. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Thomas J; Levy H; Amato S; Vockley J; Zori R; Dimmock D; Harding CO; Bilder DA; Weng HH; Olbertz J; Merilainen M; Jiang J; Larimore K; Gupta S; Gu Z; Northrup H; Mol Genet Metab; 2018 May; 124(1):27-38. PubMed ID: 29653686 [TBL] [Abstract][Full Text] [Related]
18. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model. Ahring KK; Dagnæs-Hansen F; Brüel A; Christensen M; Jensen E; Jensen TG; Johannsen M; Johansen KS; Lund AM; Madsen JG; Brøndum-Nielsen K; Pedersen M; Sørensen LK; Kjolby M; Møller LB PLoS One; 2022; 17(1):e0261150. PubMed ID: 35015767 [TBL] [Abstract][Full Text] [Related]
19. Metabolic phenotyping in phenylketonuria reveals disease clustering independently of metabolic control. Moritz L; Klotz K; Grünert SC; Hannibal L; Spiekerkoetter U Mol Genet Metab; 2023 Mar; 138(3):107509. PubMed ID: 36791482 [TBL] [Abstract][Full Text] [Related]